There is only one Cardiolite

Contact Us

We at Lantheus Medical Imaging, the makers of Cardiolite®, are committed to the professional and patient communities we serve. In the spirit of this commitment, we invite ongoing feedback and dialogue.

Corporate Information
Lantheus Medical Imaging
Bldg. 200-2
331 Treble Cove Rd.
N. Billerica, MA 01862

Phone: 1-800-362-2668
(for Massachusetts and International, call 978-667-9531)

Fax: 1-978-671-8860

Fax Orders/POs: 1-978-436-7501


Customer Service
Phone: 1-800-299-3431
Fax: 1-978-436-7501

Hours: 7:30 a.m. to 6:30 p.m. Eastern Time, Monday - Friday


Adverse Event and Product Quality Complaint Reports

United States
Phone: (800) 343-7851

  • Press Option 2 for Adverse Events
  • Press Option 2 for Product
    Quality Complaints

Fax: (978) 436-7296

Outside US/Canada
Phone: (978) 667-9531

  • Press Option 2 for Adverse Events
  • Press Option 2 for Product
    Quality Complaints
Fax: (978) 436-7296

Use appropriate country code
if outside US

E-Mail: lantheussafety@lantheus.com


Medical Information
For adverse events and product quality complaints,
please use contact information above.


Hours: 8:30 a.m. to 5:00 p.m. Eastern Time, Monday - Friday

Phone: 1-800-343-7851

  • Press Option 3, and then Option 1 for: Medical Information

Fax: 1-978-671-8736

E-Mail: medicalinformation@lantheus.com


Reimbursement Support:

Phone: 1-800-362-2668 x7995

Lantheus Medical Imaging cannot guarantee coverage or payment for products or procedures. Payer policies can vary widely and third party payment for medical products and services is affected by numerous factors.  It is always the provider's responsibility to determine and submit appropriate codes, charges, and modifiers for services rendered. For more specific information, contact your third-party payer directly in order to obtain up-to-date coverage, coding and payment information.


Contact Form

* Please complete the required fields below
* Salutation
* First Name * Last Name
* Professional Degree
* Specialty/Subspecialty
* Facility
* Address
* City
* State
* ZIP
* Telephone
Fax
* E-mail
* I am interested in the following (check all that apply):

Email adverse event and product quality complaints to:
lantheussafety@i3global.com

Email medical information inquiries to:
medicalinformation@lantheus.com

* Please enter your questions or comments below.
Do you wish to be added to our mailing list to receive additional information about Cardiolite®?

How We'll Use This Information: Lantheus Medical Imaging may collect data from you that you provide to us voluntarily, such as your name, postal address, e-mail address, telephone number and other personal information, such as your education level, professional affiliation, marital status, or personal medical information. If you provide us with these data, you agree that we may contact you to provide you with information we believe may be of interest to you.

Your information may be provided to other parties that Lantheus Medical Imaging is working with in order to help develop programs and provide services that may be of interest to you or for processing, mailing, and/or Internet-based delivery purposes within authorized Lantheus Medical Imaging personnel in other countries. At all times, personal data are treated confidentially.

If at any time you do not wish us to contact you or if you have any questions concerning our privacy practices, please feel free to contact us at bi.webadmin@lantheus.com.

 

Lantheus Medical Imaging

Indications and Usage for Cardiolite®:
Myocardial Imaging:  CARDIOLITE® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions.  CARDIOLITE® evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g. exercise or pharmacologic stress in accordance with the pharmacologic stress agent’s labeling).

CONTRAINDICATIONS:
None known.

IMPORTANT SAFETY INFORMATION: 

CARDIOLITE® has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria.  In some patients the allergic symptoms developed on the second injection during CARDIOLITE® imaging.  The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell.

Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Section 5.2). Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction and cerebrovascular events.

WARNINGS AND PRECAUTIONS:
In studying patients in whom cardiac disease is known or suspected, care should
be taken to assure continuous monitoring and treatment in accordance with safe,
accepted clinical procedure.

Caution should be exercised and emergency equipment should be available when administering CARDIOLITE®.

Before administering CARDIOLITE® patients should be asked about the possibility of allergic reactions to either CARDIOLITE® or MIRALUMA®.
MIRALUMA® is an identical compound used in breast imaging.

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Please see full Prescribing Information: Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)

Indications and Usage for Thallous Chloride Tl 201 Injection:
Thallous Chloride TI 201 Injection may be useful in myocardial perfusion imaging using either planar or SPECT (Single Photon Computed Tomography) techniques for the diagnosis and localization of myocardial infarction.  It may also have prognostic value regarding survival, when used in the clinically stable patient following the onset of symptoms of an acute myocardial infarction, to assess the site and size of the perfusion defect.

Thallous Chloride TI 201 Injection may also be useful in conjunction with exercise stress testing as an adjunct in the diagnosis of ischemic heart disease (atherosclerotic coronary artery disease).

It is usually not possible to differentiate recent from old myocardial infarction, or to differentiate between recent myocardial infarction and ischemia.

Thallous Chloride TI 201 is indicated also for the localization of sites of parathyroid hyperactivity in patients with elevated serum calcium and parathyroid hormone levels.  It may also be useful in pre-operative screening to localize extrathyroidal and mediastinal sites of parathyroid hyperactivity and for postsurgical reexamination.  Thallous Chloride Tl 201 Injection has not been adequately demonstrated to be effective for the localization of normal parathyroid glands.

CONTRAINDICATIONS: None known.

Important Safety Information:
 Following the administration of Thallous Chloride Tl 201  Injection, adverse anaphylactoid reactions have been reported (characterized by cardiovascular, respiratory, and cutaneous symptoms), some severe enough to require treatment.  Hypotension, pruritus, flushing and diffuse rash which responds to antihistamines have been reported.  Other reported events include itching, nausea/vomiting, mild diarrhea, tremor, shortness of breath, chills, fever, conjunctivitis, sweating and blurred vision.

WARNINGS:
In studying patients in whom myocardial infarction or ischemia is known or suspected, care should be taken to assure continuous clinical monitoring and treatment in accordance with safe, accepted procedure.  Exercise stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation equipment.
The vial stopper contains dry natural rubber latex and may cause allergic reactions in providers or patients who are sensitive to latex.

PRECAUTIONS:
Data are not available concerning the effect of marked alterations in blood glucose, insulin, or pH (such as is found in diabetes mellitus) on the quality of Thallous ­Chloride TI 201 Injection scans.  Attention is directed to the fact that thallium is a potassium analog, and since the transport of potassium is affected by these factors, the possibility exists that the thallium may likewise be affected.

General

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Thallous Chloride TI 201 Injection, as all radioactive materials, must be handled with care and used with appropriate safety measures to minimize external radiation exposure to patients and to clinical personnel. 

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

Please see full Prescribing Information: Thallous Chloride Tl 201 Injection